Drug Database
PR

prednisolone

✓ Approved

Takeda · NR3C1 · Small Molecule

What is prednisolone?

prednisolone is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

prednisolone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

prednisolone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

Related Research Articles

PubMedAnnals of medicine and surgery (2012)2026-11-12

Stroke in postpartum: a case report on rare presentation of primary Sjögren's syndrome.

Pandey Sabal S, Batajoo Ashim A

Sjögren's syndrome is a systemic disease that can affect all organs. Postpartum stroke is a rare presentation of Sjögren's syndrome, requiring a multidisciplinary approach. A 10-day postpartum 28-year-old woman presented with an acute onset of right-sided weakness with deviation of the mouth to the left. She also complained of dryness of the eyes, generalized fatigability, and intermittent generalized aches and pains. On examination, power in the right upper and lower limbs was 1/5, with a right upper motor neuron-type facial palsy and a positive Babinski sign. Non-contrast computed tomography and magnetic resonance imaging were diagnostic of an infarct involving the left frontal and parietal lobes. Carotid Doppler ultrasonography showed near-complete occlusion of the internal carotid artery. Tear film break-up time showed moderate dry eyes. Tests for rheumatological conditions showed a positive antinuclear antibody, and tests for extractable nuclear antigens showed positive anti-SS-A and anti-Ro-52. We diagnosed the case as a stroke due to clinically suspected Sjögren's syndrome-associated large-vessel vasculitis and started the patient on prednisolone, azathioprine, and hydroxychloroquine, with a steroid taper over 4 weeks. Postpartum stroke presents challenges in management because studies of thrombolytic therapy for stroke list pregnancy as an exclusion criterion. Our patient did not receive thrombolytic therapy; instead, she was managed with prednisolone, azathioprine, and hydroxychloroquine, with tapering of the steroid over 4 weeks. This case report highlights the challenges of postpartum stroke management and the roles of thorough investigations and interdisciplinary coordination.

PMID 43017686
Read full article →
PubMedMedicine2026-11-11

Intravascular large B-cell lymphoma presenting as unilateral lymphedema in a patient with rheumatoid arthritis and sarcoidosis: A case report.

Kimura Masatoshi M, Sasaki Haruka H, Kudo Risa R, Murai Masayuki M et al.

Intravascular large B-cell lymphoma (IVLBCL) is an uncommon subtype of diffuse large B-cell lymphoma, typically presenting with nonspecific symptoms and lacking lymphadenopathy or visible tumor lesions, which makes early diagnosis challenging. A 66-year-old female developed progressive unilateral lymphedema despite ongoing treatment for rheumatoid arthritis and sarcoidosis. Sarcoidosis-related lymph node lesions were also considered as a potential cause, and the prednisolone dose was increased. Despite these measures, the edema worsened, and a fever of around 38°C developed. At the initial evaluation, the serum soluble interleukin-2 receptor level was already elevated at 9985 U/mL. Initial investigations, including imaging, bone marrow aspiration, and random skin biopsies, failed to reveal malignancy. Subsequent monitoring revealed that the serum level of serum soluble interleukin-2 receptor had risen further to 19,835 U/mL and that thrombocytopenia was present, prompting a repeat random skin biopsy that ultimately confirmed IVLBCL through the identification of intravascular cluster of differentiation 20-positive lymphoma cells. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was initiated. However, the patient developed peripheral neuropathy, suspected to be an adverse drug reaction. Consequently, the regimen was switched to polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone. After completing 8 courses, the patient achieved remission. The left lower-limb lymphedema improved significantly. This case highlights several clinically significant points: first, IVLBCL can present solely as unilateral lymphedema without detectable lymph node enlargement or tumorous lesions, underscoring the diagnostic difficulty. Second, repeated random skin biopsies, including adipose-rich vascular tissue, are crucial in establishing a definitive diagnosis when initial biopsies are inconclusive. Third, patients with underlying autoimmune conditions such as rheumatoid arthritis and sarcoidosis, particularly those receiving immunosuppressive therapies, may have an increased susceptibility to lymphoma, suggesting that systemic immune dysregulation could contribute to disease onset.

PMID 43012796
Read full article →
PubMedCase reports in oncological medicine2026-11-11

Orbital Diffuse Large B-Cell Lymphoma Masquerading as Periorbital Cellulitis in a Paediatric Patient With Ataxia-Telangiectasia: A Case Report.

Alabdulrazzaq Fajer F, Alkanderi Arwa A, AlHazeem Bashayer B, Alenezi Abdullah A

Ataxia-telangiectasia (A-T) is a rare autosomal recessive disorder characterised by cerebellar ataxia, combined immunodeficiency and elevated predisposition to lymphoid malignancy, rendering orbital malignancy clinically and radiologically indistinguishable from infection. We report a 7-year-old female with A-T presenting with left periorbital cellulitis unresponsive to prolonged antimicrobial therapy, surgical drainage and antifungal escalation. Incisional biopsy of a persistent periorbital mass revealed diffuse large B-cell lymphoma (DLBCL), confirmed on immunohistochemistry. Staging indicated Lugano-modified Ann Arbour Stage IV disease, with a primary orbital mass and non-contiguous mediastinal and abdominal disease on cross-sectional imaging. Bone marrow assessment showed no morphological involvement, although flow cytometry detected a light chain-restricted B-cell population. The pulmonary lesions could not be radiologically distinguished from necrotising infection. She received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) with cyclophosphamide and vincristine reduced to approximately 50% of standard doses but died approximately 2 months after diagnosis, following a severe necrotising pulmonary infection after the second treatment cycle. This case underscores the importance of early malignancy consideration in immunocompromised A-T patients with refractory orbital disease, the critical role of timely tissue biopsy and the diagnostic difficulty of distinguishing lymphomatous involvement from infection on imaging alone in this population.

PMID 43011227
Read full article →
PubMedClinical case reports2026-11-11

Chronic Calcific Pancreatitis as the Probable Initial Manifestation of Systemic Lupus Erythematosus With Mixed Connective Tissue Disease Overlap: A Case Report.

Sazal Rashid Shahriar RS, Faisal Abdullah Al AA, Sikder Sabiha S, Ahmed Moontasir M et al.

Chronic calcific pancreatitis as the presenting manifestation of systemic lupus erythematosus (SLE) is exceedingly rare, particularly in tropical regions where it may be misattributed to tropical chronic pancreatitis (TCP). A 22-year-old Bangladeshi male farmer presented with a one-year history of recurrent postprandial epigastric pain and steatorrhea. Three months before admission, he developed inflammatory polyarthritis, a photosensitive malar rash, oral ulcers, Raynaud phenomenon, and progressive proximal muscle weakness. Investigations revealed normocytic anemia (hemoglobin 9.2 g/dL), thrombocytopenia (50 × 109/L), a positive direct Coombs test, and a broad autoantibody profile including strongly positive antinuclear antibodies, anti-dsDNA, anti-U1-RNP, anti-nucleosome, anti-Ku, and anti-ribosomal P antibodies. Computed tomography and magnetic resonance cholangiopancreatography showed chronic calcific pancreatitis with beaded main pancreatic duct dilatation (10-11 mm), diffuse intraductal calculi, and parenchymal atrophy, without features of autoimmune pancreatitis. He fulfilled the 2019 EULAR/ACR classification criteria for SLE (score 22) and the Sharp criteria for mixed connective tissue disease (MCTD) overlap. Alcohol use, gallstone disease, hypercalcemia, hypertriglyceridemia, pancreatotoxic drugs, and cassava exposure were absent, but genetic testing and serum IgG4 were unavailable. Hydroxychloroquine, prednisolone, mycophenolate mofetil, and pancreatic enzyme replacement were followed by improvement of the systemic features, including platelet normalization. On the available evidence, the pancreatic disease is most plausibly an early manifestation of SLE-MCTD overlap, although a hereditary or tropical contribution cannot be formally excluded. This case expands the spectrum of SLE-associated pancreatic disease and underscores the need for systematic autoimmune evaluation in young patients from tropical regions with unexplained chronic calcific pancreatitis.

PMID 43011214
Read full article →
PubMedJournal of medical case reports2026-11-11

Diagnostic dilemma in the management of a cervical spinal cord lesion: neuromyelitis optica spectrum disorder: a case report.

Azode Kelechi Michael KM, Balogun Simon Adewale SA, Komolafe Morenikeji Adeyoyin MA, Olasode Babatunde Josiah BJ et al.

Neuromyelitis optica spectrum disorder, known eponymously as Devic's disease, is a condition in which antibodies are elaborated against aquaporin water channels in the end foot processes of astrocytes due to autoimmune dysregulation thereby initiating a cascade of neuroinflammatory events that culminates in astrocytic injury, dysfunctional axonal blebs and demyelination of the central nervous system neurons. Its cervical spine symptoms may sometimes mimic a similar presentation of a cervical spine lesion. This is further validated by its core clinical magnetic resonance image feature of longitudinally extensive transverse myelitis bearing radiologic similarities with an intramedullary spinal cord lesion thereby resonating the need to maintain a high index of suspicion when evaluating patients with either condition. It is pertinent to highlight that while surgery may confer a potential benefit in patients with acute exacerbations of symptoms attributable to cervical spine compressive myelopathy due to the disease, the mainstay of treatment involves the use of steroids, immunosuppressive therapy and plasmapharesis. We report a case of a 50-year-old Nigerian female of Yoruba ethnicity who presented with progressive weakness involving all limbs of 2 weeks' duration. She had associated history of photophobia and a 1-week history of fever with sore throat a month prior to presentation. Cranial and cervical spine T2-weighted magnetic resonance imaging showed increase signal intensity within the right optic nerve and bulbous expansion with signal intensity noted in the C3-C7 segments of the spinal cord, respectively. She had C3-C6 cervical decompression surgery to relieve her symptom of progressive weakness of all her limbs with associated worsening difficulty with breathing. Laboratory investigations parameters were in keeping with neuromyelitis optica spectrum disorder and histological analysis of resected tissue specimen revealed features of neuroinflammation. She was placed among other medications, prednisolone, tenofovir, and azathioprine. She died on postoperative day 27 following development of sudden-onset respiratory distress. This article highlights the need to suspect a diagnosis of Devic's disease when evaluating patients with cervical spine lesions. It underscores the need for early diagnosis, the need for intensive ventilatory support, and the potential role of immunosuppressive therapy in improving outcomes.

PMID 43010088
Read full article →
PubMedLeukemia & lymphoma2026-11-10

Dasatinib, prednisolone, and vincristine as a 'chemo-lite' induction approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Endo Toshihide T, Takahashi Hiromichi H, Namiki Takahiro T, Hayashi Yoshiyuki Y et al.

PMID 43004503
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about prednisolone